The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2021 | CONVERSION from unresectable to resectable mCRC in real-world patients
Shahid Ahmed, PhD, MD, FRCPC, FACP, Saskatoon Cancer Center, University of Saskatchewan, Saskatoon, Canada, discussing the ongoing CONVERSION trial (NCT03401294), a pragmatic Phase II study aiming to assess the rate of conversion therapy in real-world patients with unresectable, liver-only metastatic colorectal cancer (CRC) following the combination of FOLFOXIRI and bevacizumab. The trial in progress, presented at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium 2021, also aims to determine the role of various biomarkers, including an early FDG-PT/CT response, in predicting curative hepatic metastasectomy. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
